Halozyme partners with Incyte on ENHANZE subcutaneous formulation for INCA033989 antibody

Incyte Corporation
Halozyme Therapeutics, Inc.

Incyte Corporation

INCY

0.00

Halozyme Therapeutics, Inc.

HALO

0.00
  • Halozyme entered a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using ENHANZE technology.
  • Work targets mutant calreticulin-expressing myeloproliferative neoplasms, aiming for more convenient dosing and delivery versus current development plans.
  • Terms include an upfront payment, milestone payments, royalties on net sales, and an option for Incyte to add up to two more targets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607200800PR_NEWS_USPR_____LA07615) on July 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.